Live, interactive, case based discussion - free CME/CE series
Session 1: Rapid Diagnosis, Risk Stratification, and Induction Therapies – September 17, 2025, 5:00 pm ET – 6:00 PM ET
Session 2: Evolving Treatment in Cell Therapy and Transplant – Date/Time TBD
Session 3: Coordinated Care from Treatment to Survivorship – Date/Time TBD
For each session you participate in, 1.0 credit/contact hour will be provided, for a total of 3.0 possible credits. Participation at all three sessions is encouraged but not required to obtain CME/CE credits.
Description:
The Project ECHO model is designed to create a shared learning space for healthcare professionals through a series of educational sessions, fostering peer engagement and disseminating best practices in community care. Rapid advances in the treatment of acute leukemias, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), can make treatment decisions challenging. This virtual series will help providers stay up to date on the latest in disease-specific indications, treatment with HCT and cell therapy, and post-treatment monitoring and care coordination to improve patient outcomes.
Target Audience:
This activity is intended for hematology-oncology providers, including physicians, APPs and nurses who want to learn more about managing, treating, and monitoring patients with acute leukemias including those undergoing transplant and cell therapy.
Learning Objectives:
After completing this activity, the participant should be better able to:
Session 1:
- Describe disease-specific features and indications of acute leukemias, including subtype classification
- Identify tests used to diagnose acute leukemias
- Examine therapeutic options for induction
Session 2:
- Examine the appropriate treatments for acute leukemias and timing, including allogeneic HCT and CAR T-cell therapy
- Identify and manage treatment related side effects and treatment related complications
Session 3:
- Discuss post-treatment monitoring of long-term and late effects and surveillance strategies for detecting relapse post allogeneic HCT and CAR T-cell therapy
- Identify best practices in care coordination between hematology-oncology, transplant, and other providers involved in the care of patients
Faculty:
- Alison Loren, MD, MSCE (chair/moderator)
Chief, Division of Hematology/Oncology
Director, Blood and Marrow Transplantation
C. Willard Robinson Professor of Hematology/Oncology
University of Pennsylvania
Philadelphia, PA
- Shernan Holtan, MD (chair/moderator)
Chief, Blood and Marrow Transplantation Section
Department of Medicine
Roswell Park Comprehensive Cancer Center
Buffalo, NY
Session 1
- Alice S. Mims, MD, MSCR
Acute Leukemia Research Section Head
Associate Division Director Clinical Research
Professor of Medicine
The Ohio State University Comprehensive Cancer Center
Columbus, OH
- Courtney Bellomo, MD
Hematology
New York Oncology Hematology
Albany, NY
- Meghan McGrath, MSN, RN, AGACNP-BC
Clinical Trial Nurse Navigator
Blood Cancer United
Washington, D.C.
Session 2
- Faculty TBD
Session 3
- Faculty TBD
Continuing Education Information
In support of improving patient care, this activity has been planned and implemented by Blood Cancer United and Medical Learning Institute Inc. Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Registered Nursing Designation
Approval for nurses has been obtained by the National Office of Blood Cancer United under Provider Number CEP 5832 to award 1.0 continuing education contact hours through the California Board of Registered Nursing.
Providers
This activity is provided by Blood Cancer United, NMDP and Medical Learning Institute Inc.
There is no commercial support for this activity.
For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: [email protected].